Solange Peters, MD, PhD

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Solange Peters, MD, PhD, discusses steps being taken to address the ongoing platinum chemotherapy shortage in the United States for patients with cancer.

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.